Skip to main content
Journal cover image

Immune Checkpoint Inhibitors in Gliomas.

Publication ,  Journal Article
Tan, AC; Heimberger, AB; Khasraw, M
Published in: Curr Oncol Rep
April 2017

PURPOSE OF REVIEW: Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise. RECENT FINDINGS: A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective treatment for gliomas. Biomarkers to identify characteristics of gliomas responsive to these therapies will be essential. These may include mismatch repair deficiency and high mutational load that might be germline, somatic, or acquired after therapy. Evidence on the use of immune checkpoint inhibitors in gliomas is evolving. Clinical trials are underway and results are eagerly awaited. Understanding the role of immune checkpoint inhibitors in combination with other treatment modalities for gliomas is crucial to the improvement of outcomes. The design and conduct of future clinical trials need to account for increasingly complex treatment options.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Oncol Rep

DOI

EISSN

1534-6269

Publication Date

April 2017

Volume

19

Issue

4

Start / End Page

23

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Immunotherapy
  • Humans
  • Glioma
  • Animals
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tan, A. C., Heimberger, A. B., & Khasraw, M. (2017). Immune Checkpoint Inhibitors in Gliomas. Curr Oncol Rep, 19(4), 23. https://doi.org/10.1007/s11912-017-0586-5
Tan, Aaron C., Amy B. Heimberger, and Mustafa Khasraw. “Immune Checkpoint Inhibitors in Gliomas.Curr Oncol Rep 19, no. 4 (April 2017): 23. https://doi.org/10.1007/s11912-017-0586-5.
Tan AC, Heimberger AB, Khasraw M. Immune Checkpoint Inhibitors in Gliomas. Curr Oncol Rep. 2017 Apr;19(4):23.
Tan, Aaron C., et al. “Immune Checkpoint Inhibitors in Gliomas.Curr Oncol Rep, vol. 19, no. 4, Apr. 2017, p. 23. Pubmed, doi:10.1007/s11912-017-0586-5.
Tan AC, Heimberger AB, Khasraw M. Immune Checkpoint Inhibitors in Gliomas. Curr Oncol Rep. 2017 Apr;19(4):23.
Journal cover image

Published In

Curr Oncol Rep

DOI

EISSN

1534-6269

Publication Date

April 2017

Volume

19

Issue

4

Start / End Page

23

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Immunotherapy
  • Humans
  • Glioma
  • Animals
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis